The Effectiveness and Safety of Octocog Alfa in Patients with Hemophilia A: Up to 7-year Follow-up of the Real-world AHEAD International Study

Overview

Journal Ther Adv Hematol

Specialty Hematology

Date 2024 Feb 19

PMID 38371314

Authors

Margareth C Ozelo

Cedric Hermans

Manuel Carcao

Benoit Guillet

Joan Gu

Randy Guerra

Leilei Tang

Kate Khair

Affiliations

Soon will be listed here.

Abstract

Background: Real-world data assessing treatment outcomes in patients with hemophilia A in routine clinical practice are limited.

Objective: To evaluate the effectiveness and safety of octocog alfa in patients with moderate/severe hemophilia A receiving treatment in clinical practice.

Design: The international Antihemophilic Factor Hemophilia A Outcome Database study is an observational, noninterventional, prospective, multicenter study.

Methods: This planned interim data read-out was conducted following 7 years of observation of patients receiving octocog alfa (cut-off, 30 June 2020). The primary endpoint was joint health status, assessed by the Gilbert Score. Secondary endpoints included annualized bleeding rates (ABRs), Hemophilia Joint Health Score (HJHS), health-related quality of life, consumption, and safety. This analysis stratified data by hemophilia severity at baseline [moderate, factor VIII (FVIII) 1-5%; severe, FVIII <1%].

Results: Of the 711 patients in this analysis, 582 (82%) were receiving prophylaxis with octocog alfa at enrollment, and 498 (70%) had severe disease. Median Gilbert Scores were higher with on-demand therapy prophylaxis and scores were comparable in moderate and severe disease. In patients receiving prophylaxis, there was an improvement in HJHS Global Gait Score over 7 years of follow-up overall and in patients with severe disease. ABRs and annualized joint bleeding rates were low across all 7 years. An ABR of zero was reported in 34-56% of prophylaxis patients 20-40% in the on-demand group. ABRs were similar in severe and moderate disease. In total, 13/702 (1.9%) patients experienced 18 treatment-related adverse events.

Conclusion: These data demonstrate the long-term effectiveness and safety of octocog alfa in patients with moderate and severe hemophilia A, especially in those receiving prophylaxis. The high number of patients receiving on-demand treatment experiencing zero bleeds could be due to selection bias within the study, with patients with less severe disease more likely to be receiving on-demand treatment.

Trial Registration: ClinicalTrials.gov: NCT02078427.

Citing Articles

The imperative to prevent joint bleeding in everyone living with hemophilia.

Valentino L Res Pract Thromb Haemost. 2024; 8(2):102383.

PMID: 38590364 PMC: 11000100. DOI: 10.1016/j.rpth.2024.102383.

References

Valentino L, Mamonov V, Hellmann A, Quon D, Chybicka A, Schroth P . A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012; 10(3):359-67. PMC: 3488301. DOI: 10.1111/j.1538-7836.2011.04611.x. View

Ware Jr J, Kosinski M, Keller S . A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996; 34(3):220-33. DOI: 10.1097/00005650-199603000-00003. View

Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe S . WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020; 26 Suppl 6:1-158. DOI: 10.1111/hae.14046. View

Manco-Johnson M, Abshire T, Shapiro A, Riske B, Hacker M, Kilcoyne R . Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357(6):535-44. DOI: 10.1056/NEJMoa067659. View

Oldenburg J . Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood. 2015; 125(13):2038-44. DOI: 10.1182/blood-2015-01-528414. View

Feldman B, Funk S, Bergstrom B, Zourikian N, Hilliard P, van der Net J . Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: validity of the hemophilia joint health score. Arthritis Care Res (Hoboken). 2010; 63(2):223-30. DOI: 10.1002/acr.20353. View

Khair K, Mazzucconi M, Parra R, Santagostino E, Tsakiris D, Hermans C . Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study. Haemophilia. 2017; 24(1):85-96. DOI: 10.1111/hae.13361. View

Tarantino M, Collins P, Hay C, Shapiro A, Gruppo R, Berntorp E . Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004; 10(5):428-37. DOI: 10.1111/j.1365-2516.2004.00932.x. View

Aledort L, Milligan S, Watt M, Booth J . A Retrospective Observational Study of Rurioctocog Alfa Pegol in Clinical Practice in the United States. J Manag Care Spec Pharm. 2020; 26(4):492-503. PMC: 10391008. DOI: 10.18553/jmcp.2020.26.4.492. View

10.

Klamroth R, Pollmann H, Hermans C, Faradji A, Yarlas A, Epstein J . The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study. Haemophilia. 2011; 17(3):412-21. DOI: 10.1111/j.1365-2516.2010.02435.x. View

11.

OHara J, Walsh S, Camp C, Mazza G, Carroll L, Hoxer C . The impact of severe haemophilia and the presence of target joints on health-related quality-of-life. Health Qual Life Outcomes. 2018; 16(1):84. PMC: 5932770. DOI: 10.1186/s12955-018-0908-9. View

12.

Feldman B, Funk S, Lundin B, Doria A, Ljung R, Blanchette V . Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG). Haemophilia. 2008; 14 Suppl 3:162-9. DOI: 10.1111/j.1365-2516.2008.01750.x. View

13.

Negrier C, Shapiro A, Berntorp E, Pabinger I, Tarantino M, Retzios A . Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients. Thromb Haemost. 2008; 100(2):217-23. View

14.

Knobe K, Berntorp E . Haemophilia and joint disease: pathophysiology, evaluation, and management. J Comorb. 2017; 1:51-59. PMC: 5556421. DOI: 10.15256/joc.2011.1.2. View

15.

Santoro C, Fuh B, Le P, Maes P, Berrueco R, Mingot-Castellano E . BAY 81-8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study. Eur J Haematol. 2020; 105(2):164-172. PMC: 7497079. DOI: 10.1111/ejh.13420. View

16.

Blanchette V, Shapiro A, Liesner R, Hernandez Navarro F, Warrier I, Schroth P . Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008; 6(8):1319-26. DOI: 10.1111/j.1538-7836.2008.03032.x. View

17.

McCary I, Guelcher C, Kuhn J, Butler R, Massey G, Guerrera M . Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures. Haemophilia. 2020; 26(4):631-636. DOI: 10.1111/hae.14005. View

18.

Klamroth R, Windyga J, Radulescu V, Collins P, Stasyshyn O, Mohd Ibrahim H . Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood. 2020; 137(13):1818-1827. PMC: 8039905. DOI: 10.1182/blood.2020005673. View

19.

Manco-Johnson M, Kempton C, Reding M, Lissitchkov T, Goranov S, Gercheva L . Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost. 2013; 11(6):1119-27. DOI: 10.1111/jth.12202. View

20.

Mullins E, Stasyshyn O, Alvarez-Roman M, Osman D, Liesner R, Engl W . Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A. Haemophilia. 2016; 23(2):238-246. DOI: 10.1111/hae.13119. View